Transfusions can be a life-saving treatment of patients with sickle-cell disease (SCD).
However, availability of matched units can be limiting because of distinctive blood group …

Twenty-four percent of sickle cell disease (SCD) patients have a stroke by the age of 45
years. Blood transfusions decrease stroke risk in patients deemed high risk by transcranial …

Red blood cell (RBC) transfusion is a key treatment of patients with sickle cell disease (SCD)
but remains complicated by RBC immunization. In the present study, we evaluated the …

BACKGROUND: Alloimmunization to red blood cell (RBC) blood group antigens is a major
complication for patients with sickle cell disease (SCD), which limits the usefulness of RBC …

Red blood cell (RBC) transfusions can be life‐sustaining in chronic inherited anaemias,
such as thalassaemia, and the indications for blood transfusions in patients with sickle cell …

After reviewing the relative frequency of the causes of allogeneic blood transfusion-related
mortality in the United States today, we present 6 possible strategies for further reducing …

Over the past few decades, significant advances in the care of patients with sickle cell
disease (SCD) have led to improvements in morbidity and survival. The average life span of …

Background Transfusions are the primary therapy for thalassemia but have significant
cumulative risks. In 2004, the C enters for D isease C ontrol and P revention (CDC) …

Transfusion therapy is a key intervention in decreasing morbidity and mortality in patients
with sickle cell disease (SCD). Current indications for acute and chronic transfusion therapy …

The clinical outcomes of sickle cell disease (SCD) have vastly improved over the years in
great part as a result of advanced medical technologies, improved patient education, and …